CancerEpigenome
Financiado
Dissecting the cancer epigenome – fundamental lessons from developmental biolog...
DNA methylation is a tightly controlled mechanism that is essential for normal development and genome regulation. Although maintained in a highly static pattern across healthy tissues, DNA methylation is globally reprogrammed in n...
DNA methylation is a tightly controlled mechanism that is essential for normal development and genome regulation. Although maintained in a highly static pattern across healthy tissues, DNA methylation is globally reprogrammed in nearly all malignant cancers, including gains at thousands of gene promoters and global loss across large domains. Substantial work from our group to characterize multiple primary tumor cohorts, transgenic animal models, and cancer cell lines finds that current experimental systems rarely, if ever, capture key features of the cancer epigenome. In contrast, our parallel efforts to understand epigenetic dynamics in development suggest an alternative, highly innovative hypothesis with a clear path for investigation. We find that the epigenetic alterations in cancer very closely mirror patterns that emerge in the early placenta, a tissue that naturally acquires invasive, immune suppressive, angiogenic, metabolically plastic and mutationally tolerant properties. Notably, this cancer-like epigenome depends on dynamic, previously undiscovered configurations of regulators that can be triggered without genetic mutation. With these insights, we have innovated tractable in vitro and in vivo platforms to dissect the biochemical, genetic, and physiological properties of this unique form of genome regulation as it supports developmental processes. We believe these efforts will demonstrate that the placenta and by extrapolation the cancer epigenome reflect a switch-like reprogramming event that can be studied at high resolution. In line with the ERC-ADG program’s goals, we will pursue ambitious and critical questions, resolve long-standing paradoxes and provide a complete model of epigenetic transformation in development with direct disease implications. Our world-class interdisciplinary team, extensive preliminary data, experimental design and proven track-record will enable us to turn this grant into high-impact and translationally relevant discoveries.
ver más
Duración del proyecto: 64 meses
Fecha Inicio: 2023-08-03
Fecha Fin: 2028-12-31
Fecha Fin: 2028-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-08-03
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5